Lombard Medical (OTCMKTS:EVARF) & Spectral AI (NASDAQ:MDAI) Financial Review

Spectral AI (NASDAQ:MDAI) and Lombard Medical (OTCMKTS:EVARF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Spectral AI and Lombard Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65 million	2.70	-$7.57 million	($0.53)	-3.15
Lombard Medical	N/A	N/A	N/A	N/A	N/A

Lombard Medical has lower revenue, but higher earnings than Spectral AI.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Spectral AI and Lombard Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1	0	1	0	2.00
Lombard Medical	0	0	0	0	0.00

Spectral AI currently has a consensus price target of $4.00, suggesting a potential upside of 139.52%. Given Spectral AI’s stronger consensus rating and higher possible upside, research analysts clearly believe Spectral AI is more favorable than Lombard Medical.

Profitability

This table compares Spectral AI and Lombard Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Lombard Medical	N/A	N/A	N/A

Institutional and Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Spectral AI beats Lombard Medical on 6 of the 8 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Lombard Medical

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.